Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2009 Aug;26(8):803–814. doi: 10.1111/j.1464-5491.2009.02775.x

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Journal compilation © 2009 Diabetes UK

Re-use of this article is permitted in accordance with the Creative Commons Deed, Attribution 2.5, which does not permit commercial exploitation.

PMC Copyright notice

Incremental cost-effectiveness ratio scatter plot for lispro vs. regular insulin. Base-case analysis incremental cost-effectiveness ratio scatter plot of 1000 values of mean incremental costs plotted against mean incremental effectiveness (quality-adjusted life years gained). The scatter plot was generated for Type 1 diabetes patients treated with a basal–bolus regimen of lispro vs. regular human insulin. The majority of incremental cost–effect pairs lie in the south-east quadrant, indicating dominance for lispro vs. regular human insulin, where lispro was projected to be more effective and cost saving.